CMKLR1 and experimental autoimmune encephalomyelitis: Compared with WT controls, CMKLR1−/− mice had significantly reduced clinical signs to the dihydrotestosterone-induced polycystic ovary syndrome (Tang et al., 2016), experimental autoimmune encephalomyelitis (Graham et al., 2009), and chronic obstructive pulmonary disease (Demoor et al., 2011).